Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 150, Issue 2, 2015, Pages 231-242

  Nagaraj, Gayathri ^a   Ma, Cynthia ^b  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endocrine therapy; Estrogen receptor; Metastatic breast cancer; Resistance

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; ESTROGEN RECEPTOR;

ANIMAL; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; HUMAN; METABOLISM; METASTASIS; PATHOLOGY; POSTMENOPAUSE; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM METASTASIS; POSTMENOPAUSE; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 84925405147     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3316-4     Document Type: Review

References (109)

1. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR (2005) Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 123(1):21–27
2. Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet 365(9472):1687–1717
3. Brewster AM, Hortobagyi GN, Broglio KR et al (2008) Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100(16):1179–1183
4. National Comprehensive Cancer Network (2014) Clinical practice guidelines in oncology. Breast cancer. v. 3. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 22 Dec 2014
5. Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23):3784–3796
6. Madak-Erdogan Z, Kieser KJ, Kim SH et al (2008) Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. Mol Endocrinol 22(9):2116–2127
7. Osborne CK, Schiff R (2005) Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 23(8):1616–1622
8. Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62:233–247
9. Patani N, Martin LA (2014) Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer. Mol Cell Endocrinol 382(1):683–694
10. Kushner PJ, Agard DA, Greene GL et al (2000) Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74(5):311–317
11. Ma CX, Ellis MJ (2013) The Cancer Genome Atlas: clinical applications for breast cancer. Oncology (Williston Park) 27(12):1263–1269
12. Robinson DR, Wu YM, Vats P et al (2013) Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 45(12):1446–1451
13. Levin ER (2001) Cell localization, physiology, and nongenomic actions of estrogen receptors. J Appl Physiol (1985) 91(4):1860–1867
14. Shou J, Massarweh S, Osborne CK et al (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96(12):926–935
15. de Mora JF, Brown M (2000) AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20(14):5041–5047
16. Beatson GT (1896) On the treatment of inoperable cases of carcinoma in mamma: suggestion for new method of treatment with illustrative cases. The Lancet 148(3802):104–107
17. Love RR, Philips J (2002) Oophorectomy for breast cancer: history revisited. J Natl Cancer Inst 94(19):1433–1434
18. Buzdar AU, Hortobagyi G (1998) Update on endocrine therapy for breast cancer. Clin Cancer Res 4(3):527–534
19. Sakamoto T, Eguchi H, Omoto Y et al (2002) Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells. Mol Cell Endocrinol 192(1–2):93–104
20. Miller WR, Bartlett JM, Canney P, Verrill M (2007) Hormonal therapy for postmenopausal breast cancer: the science of sequencing. Breast Cancer Res Treat 103(2):149–160
21. Davies C, Godwin J, Gray R et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. The Lancet 378(9793):771–784
22. Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet 381(9869):805–816
23. Gray RG, Rea D, Handley K et al (2013) aTTom: Longterm effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer [abstract]. J Clin Oncol 31(suppl 5):5
24. Francis PA, Regan MM, Fleming GF et al (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372(5):436–446
25. Pagani O, Regan MM, Walley BA et al (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371(2):107–118
26. Chojecki A, Wong S, Toppmeyer D (2014) Optimal management of the premenopausal patient with estrogen receptor-positive breast cancer. Am Soc Clin Oncol Educ Book 34:e12–e15
27. Lonning PE, Eikesdal HP (2013) Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocr Relat Cancer 20(4):R183–R201
28. Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348(24):2431–2442
29. Miller WR (2004) Biological rationale for endocrine therapy in breast cancer. Best Pract Res Clin Endocrinol Metab 18(1):1–32
30. Buzdar AU, Robertson JF, Eiermann W, Nabholtz J-M (2002) An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 95(9):2006–2016
31. Goss PE, Ingle JN, Pritchard KI et al (2013) Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27–a randomized controlled phase III trial. J Clin Oncol 31(11):1398–1404
32. Miller WR, Bartlett J, Brodie AMH et al (2008) Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? The Oncologist 13(8):829–837
33. Lonning PE (2009) Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? Eur J Cancer 45(4):527–535
34. Nabholtz JM, Buzdar A, Pollak M, Arimidex Study Group et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 18(22):3758–3767
35. Bonneterre J, Buzdar A, Nabholtz J-MA et al (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92(9):2247–2258
36. Mouridsen H, Gershanovich M, Sun Y et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19(10):2596–2606
37. Paridaens RJ, Dirix LY, Beex LV et al (2008) Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 26(30):4883–4890
38. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 98(18):1285–1291
39. Vergote I, Bonneterre J, Thurlimann B et al (2000) Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. Eur J Cancer 36(suppl 4):S84–S85
40. Milla-Santos A, Milla L, Portella J et al (2003) Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. Am J Clin Oncol 26(3):317–322
41. Muss HB (2014) Adjuvant chemotherapy in older women with breast cancer: who and what? J Clin Oncol 32(19):1996–2000
42. Pan K, Chlebowski RT (2014) Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer 14(3):147–153
43. Palmieri C, Patten DK, Januszewski A, Zucchini G, Howell SJ (2014) Breast cancer: current and future endocrine therapies. Mol Cell Endocrinol 382(1):695–723
44. Johnston SR, Yeo B (2014) The optimal duration of adjuvant endocrine therapy for early stage breast cancer–with what drugs and for how long? Curr Oncol Rep 16(1):358
45. Rao RD, Cobleigh MA (2012) Adjuvant endocrine therapy for breast cancer. Oncology (Williston Park) 26(6): 541–547, 550, 552
46. Osborne CK, Wakeling A, Nicholson RI (2004) Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 90(suppl 1):S2–S6
47. Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51(15):3867–3873
48. ®)—how to make a good drug better. The Oncologist 12(7):774–784
49. Kuter I, Gee JM, Hegg R et al (2012) Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. Breast Cancer Res Treat 133(1):237–246
50. Di Leo A, Jerusalem G, Petruzelka L et al (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28(30):4594–4600
51. Di Leo A, Jerusalem G, Petruzelka L et al (2014) Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 106(1):djt337
52. Osborne CK, Pippen J, Jones SE et al (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20(16):3386–3395
53. Howell A, Robertson JFR, Quaresma Albano J et al (2002) Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20(16):3396–3403
54. Robertson JF, Osborne CK, Howell A et al (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98(2):229–238
55. Chia S, Gradishar W, Mauriac L et al (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26(10):1664–1670
56. Johnston SR, Kilburn LS, Ellis P et al (2013) Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 14(10):989–998
57. Robertson JFR, Llombart-Cussac A, Rolski J et al (2009) Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 27(27):4530–4535
58. Robertson JFR, Lindemann JPO, Llombart-Cussac A et al (2012) Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study. Breast Cancer Res Treat 136(2):503–511
59. Robertson JFR, Llombart-Cussac A, Feltl D et al (2014) Fulvestrant 500 mg versus anastrozole as firstline treatment for advanced breast cancer: overall survival from the phase II ‘first’ study. Abstract presented at the 36th Annual San Antonio Breast Cancer Conference; December 10–14, San Antonio
60. Clinical Trials.gov Web site (2013) A global study to compare the effects of fulvestrant and arimidex in a subset of patients with breast cancer. (FALCON). http://www.clinicaltrials.gov/ct2/show/NCT01602380. Accessed 2 Oct 2013
61. Brodie A, Sabnis G, Jelovac D (2006) Aromatase and breast cancer. J Steroid Biochem Mol Biol 102(1–5):97–102
62. Bergh J, Jonsson P-E, Lidbrink EK et al (2012) FACT: An open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 30(16):1919–1925
63. Mehta RS, Barlow WE, Albain KS et al (2012) Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 367(5):435–444
64. ClinicalTrials.gov Web site (2014) Fulvestrant and/or anastrozole in treating postmenopausal patients with Stage II-III breast cancer undergoing surgery. http://clinicaltrials.gov/ct2/show/NCT01953588. Accessed 1 Apr 2014
65. Bedard PL, Freedman OC, Howell A, Clemons M (2008) Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer? Breast Cancer Res Treat 108(3):307–317
66. Miller WR, Larionov AA (2012) Understanding the mechanisms of aromatase inhibitor resistance. Breast Cancer Res 14(1):201
67. Knudsen S, Jensen T, Hansen A et al (2014) Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients. PLoS One 9(2):e87415
68. Cully M, You H, Levine AJ, Mak TW (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6(3):184–192
69. Chow LM, Baker SJ (2006) PTEN function in normal and neoplastic growth. Cancer Lett 241(2):184–196
70. Katso R, Okkenhaug K, Ahmadi K et al (2001) Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17:615–675
71. Fry MJ (2001) Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? Breast Cancer Res 3(5):304–312
72. Roymans D, Slegers H (2001) Phosphatidylinositol 3-kinases in tumor progression. Eur J Biochem 268(3):487–498
73. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550–562
74. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8(8):627–644
75. Samuels Y, Wang Z, Bardelli A et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670):554
76. Ellis MJ, Lin L, Crowder R et al (2010) Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 119(2):379–390
77. Bachman KE, Argani P, Samuels Y et al (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3(8):772–775
78. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70
79. Faridi J, Wang L, Endemann G, Roth RA (2003) Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin Cancer Res 9(8):2933–2939
80. Campbell RA, Bhat-Nakshatri P, Patel NM et al (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276(13):9817–9824
81. Clark AS, West K, Streicher S, Dennis PA (2002) Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1(9):707–717
82. Miller TW, Hennessy BT, Gonzalez-Angulo AM et al (2010) Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 120(7):2406–2413
83. Ma CX, Crowder RJ, Ellis MJ (2011) Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors. Steroids 76(8):750–752
84. Bachelot T, Bourgier C, Cropet C et al (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30(22):2718–2724
85. Yardley DA, Noguchi S, Pritchard KI et al (2013) Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 30(10):870–884
86. Piccart M, Hortobagyi GN, Campone M et al (2014) Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2 [abstract]. Eur J Cancer 50(suppl 3):S1 (Abstract 1LBA)
87. Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529
88. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550–562
89. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8(8):627–644
90. Miller TW, Balko JM, Arteaga CL (2011) Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 29(33):4452–4461
91. Pacheco JM, Ma CX (2013) PI3K Inhibitors in breast cancer treatment. May 7, 2013. http://www.targetedonc.com/publications/targeted-therapies-cancer/2013/april-2013/PI3K-Inhibitors-in-Breast-Cancer-Treatment. Accessed April 1, 2014
92. Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81(3):323–330
93. Altucci L, Addeo R, Cicatiello L et al (1997) Estrogen induces early and timed activation of cyclin-dependent kinases 4, 5, and 6 and increases cyclin messenger ribonucleic acid expression in rat uterus. Endocrinology 138(3):978–984
94. Geum D, Sun W, Paik SK, Lee CC, Kim K (1997) Estrogen-induced cyclin D1 and D3 gene expressions during mouse uterine cell proliferation in vivo: differential induction mechanism of cyclin D1 and D3. Mol Reprod Dev 46(4):450–458
95. Said TK, Conneely OM, Medina D, O’Malley BW, Lydon JP (1997) Progesterone, in addition to estrogen, induces cyclin D1 expression in the murine mammary epithelial cell, in vivo. Endocrinology 138(9):3933–3939
96. Tong W, Pollard JW (1999) Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E- and cyclin A-cdk2 kinase activation, and cell proliferation in uterine epithelial cells in mice. Mol Cell Biol 19(3):2251–2264
97. Watts CK, Brady A, Sarcevic B et al (1995) Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 9(12):1804–1813
98. Lukas J, Bartkova J, Bartek J (1996) Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol 16(12):6917–6925
99. Prall OW, Sarcevic B, Musgrove EA, Watts CK, Sutherland RL (1997) Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 272(16):10882–10894
100. Thangavel C, Dean JL, Ertel A et al (2011) Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer 18(3):333–345
101. Finn RS, Dering J, Conklin D et al (2009) PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11(5):R77
102. Finn RS, Crown JP, Lang I et al (2012) Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC) [abstract]. Cancer Res 72(24 suppl):91S (Abstract S1-6)
103. Finn RS, Crown JP, Lang I et al (2014) Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). Abstract presented at: 105th Annual Meeting of the American Association for Cancer Research. San Diego, April 5–9 2014
104. ® (palbociclib). http://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_u_s_fda_accelerated_approval_of_ibrance_palbociclib. Accessed 5 Feb 2015
105. Weis KE, Ekena K, Thomas JA, Lazennec G, Katzenellenbogen BS (1996) Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol 10(11):1388–1398
106. Toy W, Shen Y, Won H et al (2013) ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45(12):1439–1445
107. Li S, Shen D, Shao J et al (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 4(6):1116–1130
108. Shao J, Li S, Crowder RJ et al (2013) Patient-derived xenograft study reveals endocrine therapy resistance of ER+ breast cancer caused by distinct ESR1 gene aberrations. Presented at: 36th Annual San Antonio Breast Cancer Conference. San Antonio, Dec 10–14 2013
109. Jeselsohn R, Yelensky R, Buchwalter G et al (2014) Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res 20(7):1757–1767